O Shaughnessy Asset Management LLC Purchases Shares of 7,025 Repligen Co. (NASDAQ:RGEN)

O Shaughnessy Asset Management LLC bought a new stake in Repligen Co. (NASDAQ:RGEN) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 7,025 shares of the biotechnology company’s stock, valued at approximately $413,000.

Several other institutional investors also recently modified their holdings of RGEN. Fiera Capital Corp grew its position in Repligen by 16.4% in the 1st quarter. Fiera Capital Corp now owns 40,747 shares of the biotechnology company’s stock worth $2,408,000 after purchasing an additional 5,753 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 23.3% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 17,200 shares of the biotechnology company’s stock worth $936,000 after acquiring an additional 3,250 shares during the period. BlackRock Inc. lifted its stake in shares of Repligen by 1.2% in the 1st quarter. BlackRock Inc. now owns 5,650,666 shares of the biotechnology company’s stock worth $333,841,000 after acquiring an additional 66,580 shares during the period. Royce & Associates LP lifted its stake in shares of Repligen by 40.6% in the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares during the period. Finally, Piedmont Investment Advisors Inc. lifted its stake in shares of Repligen by 5.9% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 9,841 shares of the biotechnology company’s stock worth $581,000 after acquiring an additional 552 shares during the period. Institutional investors and hedge funds own 84.90% of the company’s stock.

A number of analysts have recently weighed in on the stock. BidaskClub raised shares of Repligen from a “hold” rating to a “buy” rating in a research note on Friday, June 21st. Zacks Investment Research raised shares of Repligen from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a research note on Wednesday, May 1st. Finally, ValuEngine lowered shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Repligen presently has a consensus rating of “Buy” and an average price target of $64.20.

RGEN stock traded up $2.13 on Friday, hitting $85.95. 1,790,760 shares of the company’s stock traded hands, compared to its average volume of 574,833. Repligen Co. has a 1-year low of $45.00 and a 1-year high of $86.16. The firm has a market cap of $3.96 billion, a PE ratio of 117.74, a price-to-earnings-growth ratio of 5.17 and a beta of 1.00. The stock’s fifty day moving average is $73.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.84 and a current ratio of 2.18.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. The business had revenue of $60.63 million during the quarter, compared to analyst estimates of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The business’s quarterly revenue was up 35.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. On average, equities analysts expect that Repligen Co. will post 0.93 EPS for the current year.

In related news, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the sale, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Glenn L. Md Cooper sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the sale, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: Trading Ex-Dividend Strategy

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.